Scientific deep-dive

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

We recently covered what happens to people’s weight after they stop these drugs, and the answer was reassuring: an average of half a percent regained in a year. A review in Nature Reviews Endocrinology raises a different concern. The cardiovascular cost of stopping, it argues, may not show up in a weight number at all.[1] It is a hypothesis, and the review is clear that it is one. What these drugs have been shown to do for the heart while you take them is on our heart disease page.

The argument

It has three parts, and they carry different amounts of evidence.

  1. Fluctuation itself may be harmful. Weight and HbA1c variability are established risk factors for cardiovascular and microvascular events, independent of where the values settle. A cycle of losing and regaining could be worse than either state held steady.
  2. The benefit may not outlast the drug. The review notes these medicines lack anti-atherosclerotic and plaque-stabilizing effects, unlike statins, which change arterial structure. If the cardiovascular benefit depends on continued metabolic effect, it stops when the drug does.
  3. Risk may be elevated acutely on withdrawal, rather than gradually returning to baseline.

Underneath all three sits the plainer point: re-developing obesity and losing glycemic control returns someone to the risk profile they had before, and time spent at higher risk accumulates.

What is missing, in the review's own words

Few data are available regarding the incidence of hard outcomes in people discontinuing such drugs.

That sentence governs everything above.[1] Nobody has measured heart attacks, strokes or deaths in a population that stopped these drugs, against a comparable population that continued. The argument is built from mechanism and from what is known about variability in other contexts. That is a legitimate way to raise a question, but not a way to answer one. A second review published in the same period does report an association between stopping within the first year and later coronary artery disease and heart failure. We take that apparent disagreement apart in stopping as a clinical transition; the short answer is that thin observational data can support both statements at once.

This matters because of who stops and why. The commonest reason is cost, and cost is not a choice for most people who face it. An article that presented a mechanistic hypothesis as established risk would frighten people about a decision they often cannot avoid, and it would be wrong on the evidence. If stopping is being forced on you, the useful response is to ask about alternatives, not to absorb a warning nobody has verified.

How it fits with the empirical picture

The two findings do not conflict. Weight regain after stopping is, on average and in ordinary care, modest, largely because most people do something else afterward.

The cardiovascular question is different and unanswered. It is possible for average weight regain to be small while a subset who lose and regain repeatedly accumulate risk that no average captures. The individual variability noted in the discontinuation data leaves plenty of room for that.

This argument also makes a middle option more attractive: reducing the dose instead of stopping. The randomized evidence for that is covered in the maintenance trial, where rescue therapy was needed by 8% who stayed on full dose, 25% who stepped down, and 67% who stopped.

What to do with an unanswered question

  • Treat cost as a clinical problem, early. If affordability is likely to end treatment, that belongs in the conversation before starting, not after stopping.
  • Ask about reducing before stopping. A lower dose is a real option with randomized support behind it.
  • Avoid the cycle if you can. Repeated stopping and restarting is the pattern this hypothesis is most concerned about.
  • Do not read this as a reason to panic about a single interruption. Nothing here establishes that, and the review says as much.

Frequently Asked Questions

Nobody knows. A review raises the concern that weight and blood sugar fluctuation are themselves cardiovascular risk factors and that these drugs, unlike statins, do not change arterial structure, so benefit may stop when the drug does. It also states that few data exist on hard outcomes in people who discontinue.
No. Average regain in ordinary care is small, largely because most people do something else afterward. It remains possible for the average to look fine while a subset who repeatedly lose and regain accumulate risk that no average captures.
Weight and HbA1c variability are established risk factors for cardiovascular and microvascular events independently of where the values settle. That is why a cycle of loss and regain is theorized to be worse than either state held steady.
Reducing the dose has randomized evidence behind it. In one trial, rescue therapy was needed by 8% of those who stayed on their full dose, 25% of those stepped down, and 67% of those who stopped. Stepping down did better than stopping and worse than continuing.
Not on the strength of this. It is a mechanistic argument, not a measured outcome, and the review says so. The useful response is to ask about lower-cost alternatives or a reduced dose rather than to absorb a warning nobody has verified.

References

  1. 1.Ceriello A, Prattichizzo F, Mastan Sheik Abdullah AR, et al. Causes and consequences of discontinuation of GLP1RAs or tirzepatide Nature Reviews Endocrinology. 2026. PMID: 42168641.

Stopping as a Clinical Transition

A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.

6 min read

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

What People Actually Do After Stopping

Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.

5 min read

Can You Lower the Dose and Keep the Weight Off?

Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.

6 min read

Stretching Doses to Save Money

At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.

8 min read

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.1

Sesame Care

Oral orforglipron alongside the injectables

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

8.8

altRX

Compounded semaglutide from $89/month at the same price at every dose

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →